Benedikt Fritzsching

Benedikt Fritzsching

Auto-generated profile, based on publicly available information

Benedikt Fritzsching

Paediatric Pulmonology and Allergy Children's Doctor Service Heidelberg Germany

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2009 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
EFEva Fritzsching
Eva Fritzsching
PKPierre Kunz
Pierre Kunz
BMBirgitta Maurer
Birgitta Maurer
JPJohannes Pöschl
Johannes Pöschl
BFBenedikt Fritzsching
Benedikt Fritzsching

1 October 2025 in Allergy
Verified
Journal Article
Open access
CWChristian Woehlk
Christian Woehlk
TSThomas Stranzl
Thomas Stranzl
MCMarco Contoli
Marco Contoli
NFNick Freemantle
Nick Freemantle
ASAndreas Kallsoy Slaettanes
Andreas Kallsoy Slaettanes
BFBenedikt Fritzsching
Benedikt Fritzsching
Background: Respiratory allergies often begin in childhood and can progress over time, leading to increased disease burden. Allergen immunotherapy (AIT) is the only causal treatment for allergic respiratory diseases with disease‐modifying potential. While randomised trials support its efficacy in controlling allergic rhinitis (AR) and asthma symptoms, long‐term real‐world data in children remain limited. Methods: This paediatric study ( n = 11,036) was conducted within the pre‐defined framework of the REACT study, based on protocol‐specified objectives. Children (< 18 years) with physician‐diagnosed AR, with or without pre‐existing asthma, were included. AIT‐treated patients were matched 1:1 to non‐AIT controls. Effectiveness was assessed over 9 years by comparing AR and asthma medication prescriptions, using a public database covering all reimbursable AIT products. Relative differences were calculated across the full observation period. Results: AIT‐treated children (mean age 11.4 years; 62.1% male) exhibited greater reductions in AR medication use than controls (additional 9% reduction beyond 61% in controls). In children with asthma, AIT was associated with additional reductions in asthma medication use (−21% beyond −48% in controls), severe exacerbations (−21% beyond −36%), and new oral corticosteroid prescriptions (−33% beyond −41%). Age stratification revealed more pronounced AR medication reductions in younger children (0–11 years) than in adolescents (12–17 years). Conclusion: This large‐scale, real‐world study supports the long‐term effectiveness of AIT in children with AR, with or without asthma. The findings reflect improved disease control and suggest a disease‐modifying effect of AIT. Early intervention, particularly in younger children, may help mitigate the progression of allergic disease.


14 July 2015 in Pneumologie
Verified
Journal Article
Closed access
BFB Fritzsching
B Fritzsching
LDL Dai
L Dai
CBC van Bodegom
C van Bodegom
JSJ Schatterny
J Schatterny
SHS Hirtz
S Hirtz
MMMa Mall
Ma Mall
Introduction: We have previously demonstrated that mice with airway specific overexpression of the amiloride-sensitive epithelial Na+ channel (βENaC-Tg) and mice lacking the epithelial Cl- channel SLC26A9 suffer from airway surface dehydration and airway mucus obstruction, which might be implicated in the pathogenesis of allergic airway disease (Anagnostopoulou et al., JCI 2012 and Mall et al., AmJRespirCritCare Med 2008). Here, we hypothesized that airway surface dehydration and reduced mucociliary clearance may increase the susceptibility for allergic airway inflammation. Methods: Aspergillus fumigatus extract (Af) was applied by intratracheal instillations into juvenile βENaC-Tg mice or WT mice (C57BL/6) and BAL cell counts, IL-13 levels and airway hyperresponsiveness (AHR, by Flexivent lung function) were determined. Genetic deletion of the IL-4/IL13 receptor signal transducer STAT6 was introduced to βENaC-Tg mice to analyze the contribution of type 2 inflammation to the Af immune response. Furthermore, preventive treatment of βENaC-Tg mice and WT mice with amiloride was performed and BAL and IL-13 levels were determined. Results: Airway eosinophils and pulmonary IL-13 expression were significantly increased in Af-challenged compared to vehicle-treated βENaC-Tg mice. Airway hyperresponsiveness was elevated in βENaC-Tg mice and increased further in response to Af treatment. Genetic deletion of STAT6 abrogated Af-induced airway eosinophilia and IL-13 expression in βENaC-Tg mice. Preventive treatment with amiloride significantly reduced allergic inflammataion in both βENaC-Tg and WT mice. Conclusion: Collectively, our results indicate that airway surface dehydration is a risk factor for key pathologies in allergic airway disease. Amelioration of airway surface dehydration (i.e. by amiloride) might constitute a novel target for prevention and treatment of allergic airway disease. Acknowledgements: DFG (DFG MA 2081/3 – 2) *Presenting author

14 July 2015 in Pneumologie
Verified
Journal Article
Closed access
SCS Christochowitz
S Christochowitz
CBC van Bodegom
C van Bodegom
SSS Schmidt
S Schmidt
EME Maier
E Maier
MHM Hagner
M Hagner
BFB Fritzsching
B Fritzsching
Introduction: We have previously demonstrated that mice with airway specific overexpression of the epithelial Na+ channel (βENaC-Tg) exhibit airway surface dehydration and eosinophilic airway inflammation in juvenile mice (Mall MA, Am J Respir Crit Care Med 2008). We hypothesized that airway surface dehydration may increase the susceptibility for allergic airway inflammation and treatment with allergen could induce IL-13 expression in vivo. Here, we evaluated cellular sources of IL-13 expression in response to allergen treatment in wild-type and βENaC-Tg mice. Methods: Juvenile wild-type and βENaC-Tg mice were challenged intratracheally for one week with Aspergillus fumigatus (Af) extract. In vitro restimulated whole lung-derived leukocytes were analyzed for IL-13 expression by multicolor flow cytometry. Laser microdissection (LMD) of the airway epithelium and subsequent nested qPCR were performed for quantification of airway-specific mRNA expression of IL-13, IL-33, IL-25, TSLP and periostin. IL-13 expression was confirmed by immunohistochemistry with IL13-/- mice-derived lung tissue as negative control. Results: Intrapulmonary exposure of Af significantly increased airway eosinophils and pulmonary IL-13 in βENaC-Tg mice. We observed elevated numbers of pulmonary IL-13+-cells among macrophages, Th2-, B- and ILC2-cells in βENaC-Tg mice by 11-color flow cytometry, which was further increased in response to Af treatment in Th2- and ILC2-cell populations. LMD revealed airway epithelial cell-specific expression of IL-13 and IL-33 but not TSLP and IL-25 in βENaC-Tg mice. Immunostaining confirmed epithelium-mediated IL-13 protein expression, which was enhanced after Af challenge in βENaC-Tg mice. Conclusion: We demonstrate that airway surface dehydration is a risk factor for allergic airway inflammation including increased frequencies of IL-13+-cells in response to allergen. Furthermore, expression of IL-13 is not limited to Th2 cells, but also ILC2 cells and airway epithelium provide substantial amounts of IL-13 in vivo. *Presenting author

21 April 2016 in Pneumo-News
Verified
Journal Article
Closed access
BFBenedikt Fritzsching
Benedikt Fritzsching
EFEva Fritzsching
Eva Fritzsching